Excellence is just the beginning.
Services & Conditions

Conditions and Treatments

View Alphabetically

Find a Doctor
Advanced Doctor Search >

Doctors at Rush Focus on You

Octavio Vega, MDAt the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.

— Octavio Vega, MD, internist

Patricia Graham, MDI enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.

— Patricia Graham, MD, internist

Hear more from doctors at Rush.

Patients & Visitors

Patients

Directions and Parking

Locations
Health & Wellness

Health News and Advice to Fit Your Life

The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.

Maintaining a Healthy WeightMan riding bike on beachTips to help you overcome common barriers to weight maintenance.

Six Signs of Nutrient DeficiencyWoman washing carrots in sinkHair loss, headaches and other signs you may be missing key vitamins and minerals.

 

About Us

Translate

French German Italian Portuguese Russian

SBRT for Localized Prostate Cancer Study

Clinical Trial Title: 
A prospective evaluation of multi-parametric magnetic resonance imaging (mpMRI) guided stereotactic body radiation treatment for localized prostate cancer.
Clinical Trial Protocol ID: 
15060207
Clinical Trial Investigator Name: 
Dian Wang, MD, PhD
Clinical Trial Protocol Description: 

A type of imaging called multi-parametric magnetic resonance imaging (mpMRI) has been approved to detect aggressive, high-grade, invasive prostate cancer. This is considered the standard care for prostate cancer. An MRI is a type of scan that uses magnets, radio waves, and a computer to produce images of body structures. The purpose of this study is to evaluate the effects, good and/or bad, of using mpMRI to guide high-dose radiation treatment for prostate cancer.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a diagnosis of prostate cancer within 1 year.
  • Have no distant metastases or regional lymph node involvement.
  • Have no use of finasteride within 30 days.
  • Have no use of dutasteride within 90 days.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Genitourinary Cancers
Contact Phone: 
(312) 942-0836
Contact Name: 
Adrianne Kajmowicz, RN, BSN